x

Posted 31 October, 2023

GELESIS HOLDINGS, INC. appointed new CEO

CEO Change detected for ticker OTC:GLSH in a 8-K filed on 31 October, 2023.


  Concurrent with the Bankruptcy Filing, on October 30, 2023, Yishai Zohar, President, Chief Executive Officer, Interim Principal Financial Officer and Principal Accounting Officer, Treasurer, Chief Compliance Officer and Corporate Secretary, and David Pass, Chief Operating Officer and Chief Commercial Officer, tendered their resignations, effective October 30, 2023.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of GELESIS HOLDINGS, INC.
Health Care/Life Sciences • Biotechnology
Gelesis Holdings, Inc. operates as a biotechnology company. The firm engages in developing a novel category of therapies for weight management and gut related chronic diseases. The company was founded on February 15, 2006 and is headquartered in Boston, MA.
Market Cap
$0.07K
View Company Details
GELESIS HOLDINGS, INC. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Concurrent with the Bankruptcy Filing, on October 30, 2023, Yishai Zohar, President, Chief Executive Officer, Interim Principal Financial Officer and Principal Accounting Officer, Treasurer, Chief Compliance Officer and Corporate Secretary, and David Pass, Chief Operating Officer and Chief Commercial Officer, tendered their resignations, effective October 30, 2023. As of October 30, 2023, the Company has no officers, consultants or employees.


Concurrent with the Bankruptcy Filing, on October 30, 2023, directors Paul Fonteyne (Chair), Alison Bauerlein, Kathryn Cavanaugh, Clayton Christopher, Jane Wildman and Yishai Zohar resigned as members of the Company's Board of Directors. The Company has no current members of the Board of Directors.